News|Articles|April 21, 2026

Contagion Survey: We Need Your Feedback

Fact checked by: Justin Mancini

Our short survey underscores the critical role of audience feedback in shaping more relevant, impactful infectious disease coverage.

We have launched a new audience survey aimed at better understanding the needs, preferences, and challenges of our readership. The initiative reflects a growing recognition that meaningful engagement with health care professionals, researchers, and stakeholders is essential to delivering timely and valuable content.

By inviting readers to share their perspectives, Contagion is taking an important step toward ensuring its reporting aligns with the realities faced on the front lines of infectious disease. Feedback collected through the survey will help identify gaps in coverage, highlight emerging topics of interest, and refine how information is delivered to maximize impact.

Understanding an audience is particularly critical in a field as rapidly evolving as infectious diseases, where new data, treatments, and public health threats constantly reshape the landscape. Surveys provide a direct line of communication, allowing readers to voice what matters most to them, whether it is clinical insights, policy updates, or real-world case experiences.

By listening to our audience, Contagion can continue to serve as a trusted, relevant resource in an ever-changing global health environment.

To fill out the survey, interested participants can go here.

Thank you for your consideration! We look forward to your feedback!


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.